AbCellera Biologics Inc. (ABCL) - 10-K Summary
Business Context and Reporting Period
Company: AbCellera Biologics Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: AbCellera is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines. The company has transitioned from a partnership-focused model to a clinical-stage biotech developing its own internal pipeline. In 2025, the company completed its 130,000-square-foot clinical manufacturing facility and initiated clinical trials for its first two internal drug candidates, ABCL635 (vasomotor symptoms) and ABCL575 (atopic dermatitis).
Key Financial Metrics
| Metric (in millions USD) | 2025 | 2024 |
|---|---|---|
| Total Revenue | $75.1 | $28.8 |
| Net Loss | $(146.4) | $(162.9) |
| Loss Per Share (Basic & Diluted) | $(0.49) | $(0.55) |
| Operating Expenses | $292.2 | $343.6 |
| Cash, Cash Equivalents & Marketable Securities | $533.8 | $625.6 |
| Net Cash Used in Operating Activities | $(131.3) | $(108.6) |
Liquidity: As of December 31, 2025, the company held approximately $533.8 million in cash, cash equivalents, and marketable securities. Management believes this liquidity is sufficient to fund operations for at least the next 36 months.
Material Changes vs. Prior Period
- Revenue Surge: Total revenue increased 161% to $75.1 million, driven primarily by a $36.0 million upfront payment from a patent litigation settlement with Bruker Cellular Analysis and $10.8 million in licensing revenue. Research fees remained relatively flat at $27.2 million.
- Reduced Impairment Charges: Depreciation, amortization, and impairment expenses decreased 76% to $22.2 million. This contrasts with 2024, which included $64.0 million in impairment charges related to in-process research and development (IPR&D) from the Trianni and TetraGenetics acquisitions.
- Operational Milestones: The company initiated Phase 1/2 trials for ABCL635 and Phase 1 trials for ABCL575. It also opened its new clinical manufacturing facility in late 2025.
- Expense Management: Total operating expenses decreased by $51.4 million year-over-year, largely due to the absence of the large impairment charges recorded in 2024. Research and development expenses increased 12% to $186.8 million due to pipeline advancement.
Guidance, Outlook, and Risks
Outlook: The company expects to continue incurring losses and negative operating cash flow in the near-to-medium term as it advances its internal pipeline. It anticipates topline data readouts for ABCL635 in Q3 2026 and ABCL575 in Q4 2026. The company does not anticipate the need for additional external funding for at least 36 months.
Key Risks:
- Clinical Development: Success depends on the advancement of internal drug candidates, which face inherent risks of failure in clinical trials.
- Profitability: The company has incurred losses since inception and may not achieve profitability if it cannot generate sufficient revenue from out-licensing or drug sales.
- Intellectual Property: Ongoing litigation with the Estate of John Schrader regarding patent infringement and partnership disputes poses potential financial and operational risks.
- Regulatory: Delays in regulatory approvals or requirements for additional bridging studies (e.g., FDA acceptance of Canadian trial data) could impact timelines.
Investor Verification Checklist
- Revenue Quality: Verify the sustainability of revenue streams, noting that a significant portion of 2025 revenue ($36.0M) was a one-time litigation settlement.
- Cash Burn Rate: Monitor the $131.3 million net cash used in operating activities against the $533.8 million liquidity position to assess runway.
- Clinical Timelines: Track the Q3 2026 and Q4 2026 data readout dates for ABCL635 and ABCL575 as critical value inflection points.
- Manufacturing Utilization: Assess the cost and utilization of the newly opened 130,000-square-foot GMP facility.
- Legal Proceedings: Review the status of the Schrader litigation and any potential financial exposure.